DCTH, ZLCS & Extended Watchlist

Delcath Systems, Inc.  DCTH
Following its inclusion in yesterday morning’s extended watchlist, DCTH would go on to have a massively successful day of trading. The stock, after briefly touching a bottom at the .402-mark, went on an absolute tear as it reached a high .66 around lunchtime.

A single-session gain of 64% on the first day we placed DCTH on our watchlist is certainly nothing to sneeze at, and given the circumstances behind the upward surge, that may have only been the beginning.

The company received word from the FDA that its Primary Liver Disease treatment, ChemoSat, had received “orphan drug” designation, a classification which denotes a drug or procedure that is aimed at a disease which affects less than 200,000 people. About 26,000 Americans are diagnosed with Primary Liver Disease each year.

(Thomson Reuters ONE via COMTEX) — New York, NY – October 1, 2013 – Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company orphan drug designation for melphalan in the treatment of patients with hepatocellular carcinoma (HCC, or primary liver cancer). >>>FULL STORY

Side Note:
We rarely see stocks in this price range with an active options chain, but DCTH is an exception. The 12/21 .50 Calls jump out at us at first glance. If the stock were to approach a dollar between now and the expiration date, one could be looking at triple-digit gains.


Zalicus, Inc. ZLCS

Coincidentally, ZLCS, a stock that we’ve been following since the beginning of last month, also received a recent FDA orphan drug designation for its experimental Z160 drug, intended for the treatment of pain related to the Shingles.

Hitting a high of 1.38 yesterday, we finally saw ZLCS fill the gap on the chart that we had been pointing out for some time. Since we’ve been following ZLCS, we’ve seen a low of .78, and yesterday’s high represents a 77% gain off of that bottom. The filling of that gap was a pretty good indicator that it was time to take profits off of the table, so we certainly hope that folks were able to take advantage.

This morning, they also announced a reverse split, the result of which should be the stocks continued listing on the Nasdaq Capital Market, as it should enable shares to remain above the 1.00 minimum bid price required for listing. We would expect shares to come away from this split valued in the $6.00-range, and sure enough, we are seeing trades go off as high as 6.45 pre-market.

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of Zalicus common stock, effective as of October 3, 2013 at 12:01 a.m. Eastern Time…The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 147.5 million to approximately 24.6 million. >>> FULL STORY


Extended Watchlist:

VICL, CRRS, CIMT, MNTG, RNN, MSTX

IWEB, ZLCS & Extended Watchlist

IceWEB, Inc. IWEB
Most of you will recall our coverage of IWEB, which began on July 9thand lasted through August. During that time, we saw the stock make a nice move off of its then-52 week lows, traversing its way from a low of .023 all the way up to .042, an 83% overall move, while also posting several hundred percent in cumulative gains during that time.You might also remember our outlining of the company’s aspirations to make the shift from cloud storage alone, to a full-range cloud services provider, and today, we received confirmation that the transition has been achieved, with the completion of the company’s most recent acquisition.

This is occurring shortly after we’ve seen IWEB come off of a new 52-week low, so the timing on this could actually work in our favor. We are going to have IWEB on bottom-watch as it searches for a base here, as well as watching for reaction to the good things the company obviously has going on behind the scenes.

STERLING, Va., Oct 01, 2013 (BUSINESS WIRE) — IceWEB, Inc. – (OTC BB:IWEB), today announced that it has completed its acquisition of Computers and Tele-Comm, Inc. and KC-NAP, LLC of Kansas City (collectively “CTC”). Details will be filed in a Form 8-K with the Securities and Exchange Commission. >>> FULL STORY

More Info:
www.iceweb.com


Zalicus, Inc. ZLCS

We caught ZLCS at a low of .78 last Friday, and mentioned it once again yesterday morning as we believed the stock was in for “another substantial move upward”. The stock did indeed turn in a nice performance yesterday, hitting a high of 1.20, a 17% intraday move, and an increase of 54% from Friday’s low. Rapid increases over such a short time period for a NASDAQ-traded stock are impressive to say the least.

In addition to another fruitful trading session with regard to price-per-share, ZLCS landed us an honorable mention on yesterday’s Penny Stock Rumble for picking the stock with the highest daily dollar volume.


Extended Watchlist:

NNRX, ALVR, EDG, LXRX

FREE, ZLCS, ARQL & Extended Watchlist

FreeSeas, Inc. FREE

It seems yesterday’s news that FREE orchestrated a deal to clean roughly $30M of debt on its balance sheet was well received, as the stock continued its recent unptrend. After we pointed out FREE gapping up into the tune of .63 in yesterday morning’s report, the stock touched a daily low .622 before rocketing to a high of .93, good for a 50% intraday gains.

The 200DMA sitting at .99 is going to be the next major resistance hurdle for FREE. Granted the fact that the stock is up approximately 660% from recent lows, it certainly may be a time to start thinking about taking profits off of the table in anticipation of a pullback.


Zalicus, Inc. ZLCS

ZLCS is a morning gapper that popped up on our scanners today. The stock recently made a nice 94% move (.48-.93) from the beginning of August to the beginning of September. The chart looks ripe, with a recent golden cross taking place, and the stock making higher highs and higher lows. The level of support in September has been .71, and main resistance is sitting at .93. This will be a stock that we want to keep an eye on going forward.

ZLCS is a biopharma company that develops treatments for pain, and currently has a drug undergoing Phase 1b clinical study.


ArQule, Inc. ARQL

Speaking of stair-steppers, ARQL has been on a tear since last Thursday when it touched a low of 2.12. Yesterday the stock reached a high of 2.53, a move of 19%

Both yesterday and the day prior, ARQL had breached the 50DMA at 2.47. We’re watching the stock currently gapping up to the tune of 2.88, up another .41 (+16%) from yesterday’s close.  In breaking the 2.80 mark in premarket trading this morning, the stock has surpassed a a recent level of resistance around 2.80. Any time we find a big-board stock with this kind of momentum, we like to pay close attention.

The next levels of resistance that will need to be cleared is sitting at 3.05 and 3.10, swing-highs from May and April, respectively.


Extended Watchlist:

SNTA, AXAS, NEWL, NKE,